A Virginia Democrat and South Dakota Republican this afternoon reintroduced bipartisan legislation in the U.S. House to protect 340B covered entities and contract pharmacies from discrimination by insurers and pharmacy benefit managers.
Reps. Abigail Spanberger (D-Va.) and Dusty Johnson (R-S.D.)
…
Drug maker Novartis told a federal appeals court in Washington, D.C. Tuesday its revised 340B contract pharmacy policy “does not impact the legal arguments at issue” in its 340B contract pharmacy case awaiting the court’s decision.
If the court disagrees,
…
Two Republican U.S. senators expressed concerns about pharmacy benefit manager encroachment on 340B covered entity savings during a Senate Finance Committee hearing on PBMs last week.
“I often hear concerns from South Dakota hospitals and health centers when it comes
…
Requiring hospitals to report what they make from 340B drug discounts versus what they spend on charity care could be a first step toward tackling full-scale 340B program reform later, a senior Republican on the U.S. House committee with jurisdiction
…
Health care providers in Mississippi eligible to participate in the 340B program may do so immediately, rather than having to wait for the next normal quarterly registration period July 1-15, federal health officials said yesterday.
Strong tornadoes struck the state
…
U.S. Health and Human Services Secretary Xavier Becerra said today that the 340B program “doesn’t have the transparency we need” and “we are going to do what we can to make it more transparent.”
Becerra was asked about the drug
…
The 340B program was discussed at length today during a U.S. House subcommittee hearing on price transparency and consolidation in health care, with three Republicans questioning whether hospitals are abusing the program and two Democrats and a Republican cautioning against
…
Ryan White Clinics for 340B Access has announced it opposes the drug industry’s joint plan with community health centers to restructure the 340B program, saying it will increase manufacturers’ “already astronomical profits at the expense of safety net providers.”
Hemophilia
…
Biopharmaceutical company Dermavant Sciences is giving refunds to health care providers that paid above the 340B ceiling price for Vtama, a non-steroidal cream to treat plaque psoriasis.
The U.S. Health Resources and Services Administration posted Dermavant’s notice to 340B covered
…
×
*Sign up for news summaries and alerts from 340B Report